A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis
Status:
Completed
Trial end date:
2019-04-12
Target enrollment:
Participant gender:
Summary
This 4-week study will evaluate the safety, pharmacokinetics (PK), and efficacy of
crisaborole ointment 2%, applied twice daily (BID) in subjects who are 3 months to less than
24 months of age with mild-to-moderate AD.